Excited to announce that our latest research for SIG-1273™ and AgeIQ™ has been published in the Journal of Cosmetic Dermatology. We demonstrate that SIG-1273™ has anti-pollution properties and.
New Publication for SIG-1273™ and AGE IQ™
Dec 3, 2018
Gizmodo released an article last Friday on SIG-1459 following up on the anti-acne story after the release of the New Scientist article earlier that week. We are so happy to see such a big response to.
Last week we had two big articles written on the effects of our new compound SIG-1459 on acne, and we couldn't be more excited!
Signum presented new anti-pollution data for SIG-1273 and anti-aging benefits of Age IQ™ at the International Investigative Dermatology Conference March 16-19 in Orlando, Florida. This conference.
Signum Biosciences, INC. will be attending this years BIO International Convention in San Diego, California.
Dr. Jose Fernandez represented Signum Biosciences at this years DDRI Conference. He presented a poster"From Consumer Products to Drugs: Developing Novel Technologies in Dermatology and Neurology" .
SIG-990 aka ( DMT210) has entered into a Phase 2 Acne Rosacea Study conducted by our Dermata Therapeutics, LLC
Jan 31, 2017
Exciting news regarding our licensee, Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, announces dosing the.
Isoprenylcysteine (IPC) small molecules were discovered as signal transduction modulating compounds ~25 years ago. More recently, IPC molecules have demonstrated antioxidant and anti-inflammatory.